SGTX · Sigilon Therapeutics
Acquired Company
Lilly completed the acquisition of Sigilon Therapeutics on 8/14/2023, purchasing all outstanding shares for $14.92 per share in cash, plus one non-tradable contingent value right per share, for total potential consideration up to $126.56 per share.
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$22.47
Open
$22.47
Volume
N/A
Day Range
$22.47 - $22.47
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
8.69%
Institutional Own.
54.33%
Qtr Updated
Sep 30th 2024